Sopharma AD (BUL:SFA)

Market Cap	1.79B +84.2%
Revenue (ttm)	2.63B +22.6%
Net Income	133.52M +75.0%
EPS	0.39 +154.0%
Shares Out	525.53M
PE Ratio	8.91
Forward PE	n/a
Dividend	0.06 (1.64%)
Ex-Dividend Date	Dec 18, 2025

Volume	19,346
Average Volume	116,343
Open	1.745
Previous Close	1.775
Day's Range	1.715 - 1.750
52-Week Range	1.410 - 2.900
Beta	0.04
RSI	47.44
Earnings Date	Mar 2, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices...

• Industry: Pharmaceutical Preparations
• Founded: 1933
• Employees: 5,932
• Stock Exchange: Bulgarian Stock Exchange
• Ticker Symbol: SFA

Financial Performance

In 2025, Sopharma AD's revenue was 2.63 billion, an increase of 22.57% compared to the previous year's 2.15 billion. Earnings were 133.52 million, an increase of 74.97%.